GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) » Definitions » Additional Paid-In Capital

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) Additional Paid-In Capital : E£366 Mil(As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Additional Paid-In Capital?


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's quarterly additional paid-in capital increased from Sep. 2023 (E£0 Mil) to Dec. 2023 (E£378 Mil) but then stayed the same from Dec. 2023 (E£378 Mil) to Mar. 2024 (E£366 Mil).

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's annual additional paid-in capital declined from Dec. 2021 (E£487 Mil) to Dec. 2022 (E£398 Mil) and declined from Dec. 2022 (E£398 Mil) to Dec. 2023 (E£378 Mil).


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Additional Paid-In Capital Historical Data

The historical data trend for Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Additional Paid-In Capital Chart

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial 486.97 486.97 486.97 397.68 377.70

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 377.70 365.98

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) Business Description

Traded in Other Exchanges
N/A
Address
No. 5 Second Industrial Zone, Sixth of October City, Giza, EGY
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents is a pharmaceutical company. It is engaged in the manufacture and sale of branded generic pharmaceutical products nutraceuticals, cosmeceuticals, food supplements, medical devices, and veterinary products. The firm is engaged in therapeutic areas namely systemic anti-infectives, alimentary tract and metabolism, genitourinary system and sex hormones, cardiovascular system, nervous system, and blood and blood-forming organs.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) Headlines

No Headlines